Login to Your Account



Avalanche of ASH abstracts draws swift reaction on Wall Street

By Michael Fitzhugh
Staff Writer

Thursday, November 6, 2014

Investors and analysts scrambled Thursday to divine portent from a heap of newly released abstracts previewing December's ASH annual meeting. Karyopharm Therapeutics Inc. led the pack of abstract news gainers, with shares rising 10.7 percent to $41.73 on news that its lead candidate, selinexor demonstrated a disease control rate of 80 percent in 10 patients with relapsed and refractory aggressive NHL.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription